Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Analyst Ratings
This is a summary of current ratings for Nektar Therapeutics and Collegium Pharmaceutical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nektar Therapeutics | 1 | 1 | 6 | 0 | 2.63 |
| Collegium Pharmaceutical | 0 | 1 | 5 | 1 | 3.00 |
Nektar Therapeutics presently has a consensus price target of $106.33, indicating a potential upside of 80.90%. Collegium Pharmaceutical has a consensus price target of $47.00, indicating a potential downside of 0.06%. Given Nektar Therapeutics’ higher probable upside, equities analysts plainly believe Nektar Therapeutics is more favorable than Collegium Pharmaceutical.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Nektar Therapeutics | -192.87% | -456.53% | -57.80% |
| Collegium Pharmaceutical | 7.72% | 102.03% | 15.24% |
Risk and Volatility
Nektar Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Earnings and Valuation
This table compares Nektar Therapeutics and Collegium Pharmaceutical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nektar Therapeutics | $98.43 million | 12.15 | -$118.96 million | ($7.97) | -7.38 |
| Collegium Pharmaceutical | $631.45 million | 2.35 | $69.19 million | $1.61 | 29.21 |
Collegium Pharmaceutical has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
75.9% of Nektar Therapeutics shares are held by institutional investors. 3.7% of Nektar Therapeutics shares are held by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Collegium Pharmaceutical beats Nektar Therapeutics on 9 of the 15 factors compared between the two stocks.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
